Potency and durability of antiretroviral therapy

被引：5
|
作者：
Daar, ES [1 ]
机构：
[1] Univ Calif Los Angeles, Harbor Res & Educ Inst, David Geffen Sch Med, Torrance, CA 90502 USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2003年 / 34卷
关键词：
D O I：
10.1097/00126334-200310012-00003
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：S111 / S117
页数：7
相关论文
共 50 条
  • [1] The importance of potency and durability in HIV patient antiretroviral therapy preferences: A telephone survey
    Sherer, RD
    Fath, MJ
    Da Silva, BA
    Nicolau, AM
    Miller, NL
    [J]. AIDS PATIENT CARE AND STDS, 2005, 19 (12) : 794 - 802
  • [2] Adherence and potency with antiretroviral therapy: A combination for success
    Gathe, J
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 : S118 - S122
  • [3] Resisting resistance: Maximizing the durability of antiretroviral therapy
    Condra, JH
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (11) : 951 - 954
  • [4] Potency and vulnerability: Troubled 'selves' in the context of antiretroviral therapy
    Persson, Asha
    Newman, Christy
    [J]. SOCIAL SCIENCE & MEDICINE, 2006, 63 (06) : 1586 - 1596
  • [5] Durability of adherence to antiretroviral therapy on initial and subsequent regimens
    Gardner, Edward M.
    Burman, William J.
    Maravi, Moises E.
    Davidson, Arthur J.
    [J]. AIDS PATIENT CARE AND STDS, 2006, 20 (09) : 628 - 636
  • [6] A retrospective cohort study of the durability of antiretroviral therapy using nevirapine versus antiretroviral therapy using protease inhibitors
    Bersoff-Matcha, SJ
    McConkey, SJ
    Min, SS
    Wohl, DA
    Merrill, D
    Tilley, A
    Mundy, LM
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1206 - 1206
  • [7] Comparative potency of three antiretroviral therapy regimes in primary HIV infection
    Fidler, S
    Fraser, C
    Fox, J
    Tamm, N
    Griffin, JT
    Weber, J
    [J]. AIDS, 2006, 20 (02) : 247 - 252
  • [8] Induction of IFN alpha subtypes by TLR agonists and their potency for antiretroviral therapy
    Gerlach, N.
    Gibbert, K.
    Nair, S.
    James, C.
    Dittmer, U.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 98 - 98
  • [9] Switch to an antiretroviral treatment of expected lower potency after effective highly active antiretroviral therapy (HAART)
    Manfredi, R
    Chiodo, F
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (01) : 95 - 98
  • [10] Extending the Durability of First-Line Antiretroviral Regimens: A Pilot Study of Directly Administered Antiretroviral Therapy
    Masese, L. N.
    Graham, S. M.
    Graham, M.
    Gitau, R.
    Mwakangalu, D. M.
    Jaoko, W.
    Ndinya-Achola, J. O.
    Peshu, N.
    Mandaliya, K.
    McClelland, R. S.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E201 - E202
12345